Summary
FMEA Chart
FMS or RXST: Which Is the Better Value Stock Right Now?
Investors looking for stocks in the Medical - Instruments sector might want to consider either Fresenius (FMS) or RxSight, Inc. (RXST). But which of these two companies is the best option for those looking for undervalued stocks?
Fresenius Medical Care announces 1 bln euros share buyback programme
The world's largest dialysis specialist Fresenius Medical Care said, ahead of its capital markets day on Tuesday, that it plans to embark on a 1 billion euros ($1.16 billion) share buyback programme.
Focus Graphite Achieves 5N Purity from Lac Knife Graphite, Refined to Nuclear-Grade Purity Levels in AETC Testing
Thermal purification run on Lac Knife concentrate material produced and characterized by AETC has resulted in 99.9992 wt. % C purity – laying the foundation for the transition into the nuclear spec material purity OTTAWA, ON , June 12, 2025 /PRNewswire/ - Focus Graphite Advanced Materials Inc. (TSXV: FMS) (OTCQB: FCSMF) (FSE: FKC0) ("Focus" or the "Company") is pleased to announce that recent thermal purification testing completed by American Energy Technologies Company ("AETC") has successfully refined Lac Knife flake graphite concentrate to a purity level of 99.999 wt.
Fresenius Medical Care AG & Co. KGaA ADR Dividends
 FMEA 17 May 2024 | Other | €0.64 Per Share |
| FMEA 17 May 2023 | Other | €0.6 Per Share |
| FMEA 13 May 2022 | Other | €0.71 Per Share |
| FMEA 21 May 2021 | Other | €0.83 Per Share |
| FMEA 28 Aug 2020 | Other | €0.72 Per Share |
Fresenius Medical Care AG & Co. KGaA ADR Earnings
| 5 Aug 2025 (44 Days) Date | | - Cons. EPS | - EPS |
| 6 May 2025 Date | | - Cons. EPS | - EPS |
| 5 May 2025 Date | | - Cons. EPS | - EPS |
| 25 Feb 2025 Date | | - Cons. EPS | - EPS |
| 5 Nov 2024 Date | | - Cons. EPS | - EPS |
| FMEA 17 May 2024 | Other | €0.64 Per Share |
| FMEA 17 May 2023 | Other | €0.6 Per Share |
| FMEA 13 May 2022 | Other | €0.71 Per Share |
| FMEA 21 May 2021 | Other | €0.83 Per Share |
| FMEA 28 Aug 2020 | Other | €0.72 Per Share |
| 5 Aug 2025 (44 Days) Date | | - Cons. EPS | - EPS |
| 6 May 2025 Date | | - Cons. EPS | - EPS |
| 5 May 2025 Date | | - Cons. EPS | - EPS |
| 25 Feb 2025 Date | | - Cons. EPS | - EPS |
| 5 Nov 2024 Date | | - Cons. EPS | - EPS |
Fresenius Medical Care AG & Co. KGaA ADR (FMEA) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
What is the earnings per share?
When is the next earnings date?
Has Fresenius Medical Care AG & Co. KGaA ADR ever had a stock split?
Fresenius Medical Care AG & Co. KGaA ADR Profile
| Medical - Care Facilities Industry | Healthcare Sector | Ms. Helen Giza CEO | XSTU Exchange | DE0005785802 ISIN |
| DE Country | 112,035 Employees | 23 May 2025 Last Dividend | 4 Dec 2012 Last Split | - IPO Date |
Overview
Fresenius Medical Care AG is a leading global provider in the field of dialysis and related services, catered towards individuals suffering from renal diseases. Established in 1996 and headquartered in Bad Homburg, Germany, the company has a broad reach extending across Germany, North America, and other international locations. Fresenius Medical Care AG specializes in delivering dialysis treatment and associated laboratory and diagnostic services mainly through its extensive network of outpatient dialysis clinics. Additionally, the company holds contracts with hospitals in the United States to offer dialysis services to hospitalized end-stage renal disease (ESRD) patients and those facing acute kidney failure. Beyond its core services, Fresenius Medical Care AG is engaged in the development, manufacture, and distribution of a wide range of health care products, as well as in the development and licensing of renal pharmaceuticals. It serves a diverse clientele, including dialysis clinics, hospitals, and specialized treatment facilities, through direct sales and a blend of local sales forces, independent distributors, dealers, and sales agents.
Products and Services
Fresenius Medical Care AG provides a comprehensive suite of products and services tailored to meet the needs of renal disease patients and health care providers:
- Dialysis Services and Support: The company delivers dialysis treatment alongside laboratory and diagnostic services through its outpatient clinics. It also provides training, clinical monitoring, follow-up assistance, and home delivery of supplies for patients, alongside contracted dialysis services for hospitalized patients.
- Health Care Products: The product line includes items such as polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers, solutions, and granulates. These are essential for performing dialysis treatment both in clinics and at home.
- Renal Pharmaceuticals: Fresenius Medical Care AG works on the development, acquisition, and in-licensing of renal pharmaceuticals. The company also supplies renal medications directly to patients' homes or dialysis clinics, ensuring that those undergoing treatment have easy access to their necessary medications.
- Water Treatment Systems and Other Supplies: The comprehensive list of supplies includes bloodlines, hemodialysis concentrates, peritoneal dialysis solutions, and systems for water treatment, which ensure the safe conduct of dialysis treatment by managing the cleanliness and purity of water used.
- Cardiopulmonary and Apheresis Products: Beyond renal care, the company also offers products for acute cardiopulmonary support and apheresis procedures, addressing the needs of patients with cardiovascular issues or those requiring blood purification.
- Specialized Medical Services: Fresenius Medical Care AG provides additional specialized services, such as vascular, cardiovascular, and endovascular specialty services, ambulatory surgery center management for vascular care, and professional services for nephrology and cardiology. These are intended to complement the core dialysis services by addressing the broader health needs of renal disease patients.
Contact Information
